Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Himuro H, Nakahara Y, Igarashi Y, Kouro T, Higashijima N, Matsuo N, Murakami S, Wei F, Horaguchi S, Tsuji K, Mano Y, Saito H, Azuma K, Sasada T. Himuro H, et al. Among authors: sasada t. Cancer Immunol Immunother. 2023 Aug;72(8):2829-2840. doi: 10.1007/s00262-023-03464-w. Epub 2023 May 16. Cancer Immunol Immunother. 2023. PMID: 37188764 Free PMC article.
Enhancing Mass spectrometry-based tumor immunopeptide identification: machine learning filter leveraging HLA binding affinity, aliphatic index and retention time deviation.
Wei F, Kouro T, Nakamura Y, Ueda H, Iiizumi S, Hasegawa K, Asahina Y, Kishida T, Morinaga S, Himuro H, Horaguchi S, Tsuji K, Mano Y, Nakamura N, Kawamura T, Sasada T. Wei F, et al. Among authors: sasada t. Comput Struct Biotechnol J. 2024 Feb 3;23:859-869. doi: 10.1016/j.csbj.2024.01.023. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38356658 Free PMC article.
Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.
Nakahara Y, Kouro T, Motoyama S, Miura M, Fujita K, Igarashi Y, Higashijima N, Matsuo N, Himuro H, Wei F, Horaguchi S, Tsuji K, Mano Y, Komahashi M, Saito H, Azuma K, Sasada T. Nakahara Y, et al. Among authors: sasada t. Front Cell Dev Biol. 2024 Jan 16;11:1324898. doi: 10.3389/fcell.2023.1324898. eCollection 2023. Front Cell Dev Biol. 2024. PMID: 38469154 Free PMC article.
MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Nagasaka H, Kishida T, Kouro T, Igarashi Y, Takebe S, Yamamoto S, Kondo T, Koizumi M, Terao H, Suzuki T, Nakaigawa N, Himuro H, Wei F, Sasada T. Nagasaka H, et al. Among authors: sasada t. Int J Clin Oncol. 2024 Jun;29(6):832-839. doi: 10.1007/s10147-024-02477-4. Epub 2024 Apr 6. Int J Clin Oncol. 2024. PMID: 38580797 Free PMC article.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: sasada t. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
213 results